Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
This study is testing a newer immunotherapy drug called gotistobart against standard chemotherapy to see if it can help people live longer with a common type of lung cancer. It is designed for patients whose cancer has continued to grow even after receiving previous immunotherapy treatments.
You may be able to join if you are 18 or older, have a confirmed diagnosis of lung cancer that has spread, and have previously received standard immunotherapy and chemotherapy. There are specific rules regarding your past treatments, medications, and any other genetic mutations to ensure your safety.
Participants will be randomly assigned to receive either the new immunotherapy drug or standard chemotherapy through an IV infusion once every 21 days for up to a year. Your health and how your cancer responds will be closely monitored by the study team throughout this time.
This study has locations in several U.S. states including Alabama, Arkansas, and California. The study is currently active, though it is not actively looking for new participants right now.
- 1Compares a new immunotherapy drug called gotistobart with standard chemotherapy.
- 2Designed for adults with advanced lung cancer that progressed after prior immunotherapy.
- 3Treatments are given via IV infusion once every 21 days for up to a year.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.